You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 42 No. 2, February 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Serotonin and 5-Hydroxyindoleacetic Acid in CSF

Difference in Parkinson's Disease and Dementia of the Alzheimer's Type

Ladislav Volicer, MD, PhD; Lorne K. Direnfeld, MD; Morris Freedman, MD; Martin L. Albert, MD; Philip J. Langlais, MA; Edward D. Bird, MD

Arch Neurol. 1985;42(2):127-129.


Abstract

• Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels were measured in the sixth, 13th, and 20th milliliters of CSF in patients with dementia of the Alzheimer's type (DAT) and Parkinson's disease (PD), and in an aliquot of CSF in controls. In patients with PD there was a positive correlation between 5-HT and 5-HIAA levels in the 20th milliliter of CSF, while in patients with DAT there was a negative correlation of these levels in this CSF fraction. In patients with the senile form of DAT the 5-HIAA levels in the 20th milliliter of CSF were higher than in patients with PD. These results indicate differential involvement of the serotoninergic system in DAT and PD, and may lead to the development of a chemical marker for DAT.



Author Affiliations

From the Geriatric Research Education Clinical Center, E. N. Rogers Memorial Veterans Hospital, Bedford, Mass (Dr Volicer); Boston Veterans Administration Medical Center (Drs Direnfeld, Freedman, and Albert); the Departments of Pharmacology (Dr Volicer) and Neurology (Dr Albert), Boston University Medical School; McLean Hospital, Belmont, Mass (Dr Bird and Mr Langlais); and Harvard Medical School, Boston (Dr Bird and Mr Langlais). Dr Direnfeld is now with Maui Clinic, Kahalui, Maui, Hawaii, and Dr Freedman is now with the University of Toronto.


Footnotes

Accepted for publication April 11, 1984.

Read before the Society for Neuroscience Meeting, Boston, Nov 10, 1983.

Reprint requests to VA Hospital, GRECC, 200 Springs Rd, Bedford, MA 01730 (Dr Volicer).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia
Lanctôt et al.
J. Neuropsychiatry Clin. Neurosi. 2001;13:5-21.
ABSTRACT | FULL TEXT  

Analgesic Action of Methylphenidate on Parkinsonian Sensory Symptoms: Mechanisms and Pathophysiological Implications
Cantello et al.
Arch Neurol 1988;45:973-976.
ABSTRACT  

Serotoninergic System in Dementia of the Alzheimer Type: Abnormal Forms of 5-Hydroxytryptophan and Serotonin in Cerebrospinal Fluid
Volicer et al.
Arch Neurol 1985;42:1158-1161.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.